


# Cerebrovascular diseases

---


- Diseases with sudden onset, or rapid development, of focal cerebral dysfunction as the consequence of lesion of cerebral arteries. There are 2 types:
  - Brain ischemia (stroke) or
  - Brain haemorrhage




# Epidemiology


---



- **Incidence** – 125 – 446/100 000 inhabitants (*Feigin V.L. et al., Lancet Neurol, 2009*)
- **SLOVAKIA**
- **Mortality: 100-200/100 000**
- **Incidence: 300-500/100 000**




## Patients with stroke at ND FNLP Košice SNP 1 in years 1986 - 2002











## Thrombotic Stroke




Copyright © 2002 WebMD, Inc. All rights reserved.

## Embolic Stroke




Copyright © 2002 WebMD, Inc. All rights reserved.



# Cerebrovascular diseases



**Brain ischemia**



**Brain haemorrhage**



**Subarachnoid  
haemorrhage**

# Head injury, **NO** stroke

---




**Subduralny hematoma**



**Epidural hematoma**

# Death/ vascular diseases (AHA)






**50 % patients after stroke  
→ disabled**

**↑ Budget for stroke**


**Stroke therapy – very expensive**

# Anatomy of cerebral arteries







### Large ischemic stroke in the brain




# Vertebral arteries



Foramina transversaria






# Regulation of cerebral circulation


---

- **Blod flow - 50 – 60 ml/100 g of brain tissue/min.**
- **Blod flow below 20 ml/100 g/min.** – functional changes of neurons – reversible dysfunction (few hours)
- **Blod flow below 12, or 10 ml/100 g/min structural changes** irreversible changes – brain infarct,


Patient with poor collaterals




Multiphasic map (ESCAPE trial)




DWI




FLAIR




Day 7 DWI




Tmax




CBV



ASL CBF












Capillary phase\*




Venous phase\*

Collateral map (MRP-based)

Patient with good collaterals




Capillary phase\*




Venous phase\*

**MTT tp1  
2:45 hours**




**Prolonged  
MTT tp1**

**MTT tp2  
6:00 hours**



**Prolonged  
MTT tp2**

**Regions of  
Reperfusion**





MTT: 0 sec. 15 sec. 30 sec.

**Absolute Reperfusion = Prolonged MTT tp1 – Prolonged MTT tp2**

**Relative Reperfusion = Absolute Reperfusion / Prolonged MTT tp1**

# MRI –DWI





# Risk factors of stroke

---


## → Non modifying RF

- Age
- Sex
- Genetics

## → Modifying RF

- Hypertension
- Atrial fibrillation
- Smoking
- Hypercholesterolemia
- Alcohol
- Asympt. stenosis A/C
- Diabetes mellitus

*Sacco, Neurology 1998, 51  
(Suppl 3), S27-S30*





# Arterial hypertension (AH)

---


- – AS makroangiopathy, AS mikroangiopathy, vascular dementia, bleeding


# Atherosclerosis



## Carotid Plaque


Normal lining






**Fig 1: blockage in the carotid artery**

# Atrial fibrillation




# Atrial fibrillation



---

- AF ↑ risk of stroke 5-6-times
- CHADS<sub>2</sub> – (congestive heart failure, hypertension, age ≥ 75, diabetes, stroke)  
**≥ 2 – high risk**
- CHA<sub>2</sub>DS<sub>2</sub>-VASc – max 9 points
- **NOAC** - trombin inhibitor - **Dabigatran**, factor Xa inhibitors– **Rivaroxaban, Apixaban, Edoxaban**




# Diabetes mellitus (DM)

---


- Risk of atherotrombotic strokes, lacunes, dementia

# Trombophilia

Z.K., female, 25 years






- 3 days after delivery
- Posit. familial history
- **Deficit AT III**




# Trombophilia

L.T., man, 55 years

- Repeating strokes – leftside hemiparesis (2003, 2005), sekundary epilepsy
- Posit. familial history
- FV Leiden, MTHFR homozygot






# Classification of stroke I.

---


- Old definition
- TIA – transitory ischemic attack - lasts 1 hour
- Brain infarct – completed stroke
- New „tissue-based“ definition of TIA
- A brief episode of neurological dysfunction caused by focal brain or retinal ischemia, with clinical symptoms typically lasting less than one hour, and without evidence of acute infarction
- Ischemic stroke (brain infarct) is defined as an infarction of central nervous system tissue.



# Classification of stroke II.

---

- **Territory of a. cerebri media**
- **Territory of a. cerebri anterior**
- **Territory of a. cerebri posterior**
- **Territory of a. bazilaris (vertebrobasilar)**
- **Territory of a. carotis interna**
- **Territory of a. carotis communis**



ACA – arteria cerebri anterior,  
 MCA – arteria cerebri media,  
 PCA – arteria cerebri posterior,  
 AChA – arteria chorioidea  
 anterior,  
 SCA – arteria cerebelli superior,  
 AICA – arteria cerebelli anterior  
 inferior,  
 PICA – arteria cerebelli inferior  
 posterior,  
 LSA – lentikulostriatálne artérie.

# MCA territory


- The most often embolic etiology – very sudden onset
- Speech disorder, hemiparesis (dominantly on upper extremity, central lesion of n. VII.
- Wernicke – Mann position of the body



# ACA territory

---

- **Central paresis of lower extremity**
- **Disorders of behaviour – prefrontal sy**




# PCA territory

---

- **Visual field disorders – homonymous hemianopsia**






# BA territory

---


- **Dizziness, diplopia, nystagmus, hemiparesis or kvadruparesis, hemiplegia alternans, cranial nerves lesions, problems with deglutination and speech**



# Classification of stroke III.

---

- **Brain infarct**
- **Lacunar infarct – diameter less than 1,5 cm**




# Diagnosics of stroke

---

- **Clinical feature**
- **Brain CT**
- **Laboratory** – RBC, SR, coagulation, fibrinogen, Na, K, sugar, urea, kreatinin, cholesterol, triglycerids, **CRP**, **TPIT**
- **Duplex of carotid arteries**
- **ECHOcardiography**


# Brain CT – early signs of ischemia




# Brain CT – early signs of ischemia




# Brain CT – ischemia




# Brain CT – ischemia




# Brain CT – ischemia



# „Wake-up stroke“




**Brain MR – FLAIR**




**Brain MR – DWI**


# ICA stenosis





# ICA stenosis




# ICA stenosis



# Duplex of carotid arteries and AG





# Stroke therapy

---

- **Acute**

**1/ Trombolysis - rt-PA** (recombinant tissue plasminogen activator) -  
**≤ 4.5 hours after first symptoms!**

**2/ Thrombectomy**


**≤ 6 hours after first symptoms!**

**3/ ASA – 325 mg – later than 6 hours**

- **1/ - i.v. rt-PA 0,9 mg/kg**

- **Brain CT – negative, early signs of ischemia**

# Možnosť úpravy neurologického poškodenia trombolytickou reperfúziou



Ischemické jadro  
(mozgové tkanivo  
smerujúce k nekróze)

Penumbra  
(zachrániteľná časť  
mozgu)


Neliečny pacient stráca v ischemickej oblasti približne 1,9 milióna neurónov každú minútu

Reperfúzia ponúka možnosť redukcie rozsahu ischemického poškodenia


*Saver. Stroke 2006;37:263-266.  
González. Am J Neuroradiol 2006;27:728-735.  
Donnan. Lancet Neurol 2002;1:417-425.*

# The goal of therapy

## Compartments of Infarct Development




# Development of ischemia




# ECASS III – Clinical Benefits

## ECASS III






NNT – 2/90 min., 7/3h, 14/3-4.5h

# Trombolysis



# Endovascular therapy

## Solitaire retriever, Trevo pro retriever



# O.R. 52-years old woman



- Wake up - 5.45, she felt down, aphasia, right side hemiparesis
- Emergency
- 6.50 – hospital, NIHSS - 11
- 7.05 – brain CT
- 7.45 – rTPA
- 9.05 – DSA, trombektomy

# O.R. 52-years old woman

---



DSA before TE



DSA after TE

# O.R. 52-years old woman

---



- Brain CT after 24 hours
- mRS – 0 at time of discharge




# T.T. 37-years old man

- 30.7. 2013 –orchiektomy and CHT
- 30.8.2013 at 16.00 weakness of left extremities
- Admitted in hospital at 18.00, barin CT at 19.20
- Admitted in our hospital at 21.15, 30.8.2013



# Angiography

Trombektomy 30.8.2013 at 22.45



# CT after TE and decompressive craniotomy



After po 24 hours



After 72 hours



After 15 days



Eric Jordan sings Puccini


Adult

PVC 0



HR 73  
 150  
 50

pulse 73



SpO2 95  
 100  
 90


Perf 6

# „Wake-up stroke“




*Košice, May, 2015*



*67- year old patient , waked up at 5.30 – left side hemiparesis, NIHSS – 10 points*



**Brain MR – FLAIR**



**Brain MR – DWI**



Carotis CTM  
IODINE



4962  
1949/12/10  
65Y F  
2015/4/24  
08:35:57


0.1 FAD  
0.1 CRA  
93.0 kV  
234.0 mA  
Velikost' pixelu: 0.244 mm  
W: 713 L: 2105

Carotis CTM  
IODINE



496210334  
1949/12/10  
65Y F  
2015/4/24  
08:35:57


0.1 LAO  
9.3 CRA  
94.0 kV  
230.0 mA  
Velikost' pixelu: 0.244 mm  
W: 607 L: 2096



# Therapy after acute stroke

---


- **Therapy of risk factors – prevention**
- **Antiagregants**
- **Anticoaguants**
- **Endarterectomy (CAE) – also acute**
- **STENT**
- **Rehabilitation**



# Guidelines for antiagregants

---

- **Antiagregants**
- **Non cardioembolic strokes**
- **ASA, 50 – 325 mg 1xD**
- **Combination ASA and dipyridamol 200 mg 2xD**
- **Clopidogrel 75 mg 1xD**



# Indications for anticoagulants in patients with stroke and AF

---

- **Stroke, AF and**
- CHADS<sub>2</sub> – (congestive heart failure, hypertension, age  $\geq 75$ , diabetes, stroke)  
 **$\geq 2$  – high risk**
- **Warfarin** – INR 2,0-3,0
- **Direct oral anticoagulants**
- Direct inhibitor of thrombin – **Dabigtran**
- Inhibitors of Xa – **Apixaban, Rivaroxaban, Edoxaban**

# RELY - ARISTOTLE - ROCKET AF


Charakteristika štúdií	RELY dabigatran	ROCKET AF rivaroxaban	ARISTOTLE apixaban
Mechanizmus účinku	Ila	Xa	Xa
Počet pacientov	18 113	14 264	18 201
Dávkovanie	150 mg 2x/ day 110 mg 2x/ day	20mg 1x/ day (15mg 1x/ day )	5mg 2x/ day 2,5 mg 2x/ day
Dizajn	PROBE	Double blind	Double blind
Priemer CHADS <sub>2</sub>	2,1	3,5	2,1
Priemer TTR	64%	55%	62%
Medián TTR	67%	58%	66%
Prerušenie liečby (Warfarín)	21,2% (16,6)	23,9% (22,4)	25,3% (27,5)

Connolly SJ *et al.* *N Engl J Med* 2009; **361**:1139–1151. Connolly SJ *et al.* *N Engl J Med* 2010; **363**:1875–1876 (letter to editor).

SPC Pradaxa tvrdé tobolky 110/150 mg, 8/2011;

Granger CB *et al.* *NEJM* 2011; 10..1056/NEJMoal 1107039. [NEJM.org](http://NEJM.org); Patel MR *et al.* *NEJM* 2011;10.1056/NJMoal1009638.[NEJM.org](http://NEJM.org).

[https://www.dcri.org/news-publications/slides-presentations/ROCKET-AF-LBCT\\_FINAL.ppt/view?searchterm=rocket](https://www.dcri.org/news-publications/slides-presentations/ROCKET-AF-LBCT_FINAL.ppt/view?searchterm=rocket)






# Endarterectomy ICA

---



- **Indications**
- **ACI stenosis > 70% (in ulcerating AS plaques – risk of embolisation – > 60%)**
- **Brain CT**
- **After TIA – 2 days, small infarct within 2 weeks, others – 6 weeks after stroke**

# Endarterectomy




# Endarterectomy

---



# Carotid Stenting



Internal Carotid Artery



Plaque


Stent

External Carotid Artery


Endovascular Catheter

Common Carotid Artery







**ICA**  
**High grade stenosis - Stent**



**ICA**  
**High grade stenosis - Stent**




**ICA**  
**High grade stenosis - Stent**



# Indications of STENT

---

- **Patients with**
  - **operation risk**
  - **older patients**
  - **risk of anaesthesia**
  - **changes on the neck**
- **Restenosis after CAE**



# Advantages of STENT

---

- **Less invasive method**
- **Less patients with restenosis**
- **Shorter hospitalization**
- **Smaller risk of wound complications**